Your browser doesn't support javascript.
loading
Comparative pathogenicity of SARS-CoV-2 Omicron subvariants including BA.1, BA.2, and BA.5.
Tamura, Tomokazu; Yamasoba, Daichi; Oda, Yoshitaka; Ito, Jumpei; Kamasaki, Tomoko; Nao, Naganori; Hashimoto, Rina; Fujioka, Yoichiro; Suzuki, Rigel; Wang, Lei; Ito, Hayato; Kashima, Yukie; Kimura, Izumi; Kishimoto, Mai; Tsuda, Masumi; Sawa, Hirofumi; Yoshimatsu, Kumiko; Yamamoto, Yuki; Nagamoto, Tetsuharu; Kanamune, Jun; Suzuki, Yutaka; Ohba, Yusuke; Yokota, Isao; Matsuno, Keita; Takayama, Kazuo; Tanaka, Shinya; Sato, Kei; Fukuhara, Takasuke.
Afiliação
  • Tamura T; Department of Microbiology and Immunology, Faculty of Medicine, Hokkaido University, Sapporo, Japan.
  • Yamasoba D; Institute for Vaccine Research and Development, HU-IVReD, Hokkaido University, Sapporo, Japan.
  • Oda Y; Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Ito J; Faculty of Medicine, Kobe University, Kobe, Japan.
  • Kamasaki T; Department of Cancer Pathology, Faculty of Medicine, Hokkaido University, Sapporo, Japan.
  • Nao N; Division of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Hashimoto R; Department of Cell Physiology, Faculty of Medicine, Hokkaido University, Sapporo, Japan.
  • Fujioka Y; Global Station for Biosurfaces and Drug Discovery, Hokkaido University, Sapporo, Japan.
  • Suzuki R; AMED-CREST, Japan Agency for Medical Research and Development (AMED), Tokyo, Japan.
  • Wang L; Institute for Vaccine Research and Development, HU-IVReD, Hokkaido University, Sapporo, Japan.
  • Ito H; Division of International Research Promotion, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan.
  • Kashima Y; One Health Research Center, Hokkaido University, Sapporo, Japan.
  • Kimura I; Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan.
  • Kishimoto M; Department of Cell Physiology, Faculty of Medicine, Hokkaido University, Sapporo, Japan.
  • Tsuda M; Global Station for Biosurfaces and Drug Discovery, Hokkaido University, Sapporo, Japan.
  • Sawa H; AMED-CREST, Japan Agency for Medical Research and Development (AMED), Tokyo, Japan.
  • Yoshimatsu K; Department of Microbiology and Immunology, Faculty of Medicine, Hokkaido University, Sapporo, Japan.
  • Yamamoto Y; Institute for Vaccine Research and Development, HU-IVReD, Hokkaido University, Sapporo, Japan.
  • Nagamoto T; Department of Cancer Pathology, Faculty of Medicine, Hokkaido University, Sapporo, Japan.
  • Kanamune J; Institute for Chemical Reaction Design and Discovery (WPI-ICReDD), Hokkaido University, Sapporo, Japan.
  • Suzuki Y; Department of Microbiology and Immunology, Faculty of Medicine, Hokkaido University, Sapporo, Japan.
  • Ohba Y; Graduate School of Frontier Sciences, The University of Tokyo, Kashiwa, Japan.
  • Yokota I; Division of Molecular Pathobiology, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan.
  • Matsuno K; Department of Cancer Pathology, Faculty of Medicine, Hokkaido University, Sapporo, Japan.
  • Takayama K; Institute for Chemical Reaction Design and Discovery (WPI-ICReDD), Hokkaido University, Sapporo, Japan.
  • Tanaka S; Institute for Vaccine Research and Development, HU-IVReD, Hokkaido University, Sapporo, Japan.
  • Sato K; Division of International Research Promotion, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan.
  • Fukuhara T; One Health Research Center, Hokkaido University, Sapporo, Japan.
Commun Biol ; 6(1): 772, 2023 07 24.
Article em En | MEDLINE | ID: mdl-37488344
ABSTRACT
The unremitting emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants necessitates ongoing control measures. Given its rapid spread, the new Omicron subvariant BA.5 requires urgent characterization. Here, we comprehensively analyzed BA.5 with the other Omicron variants BA.1, BA.2, and ancestral B.1.1. Although in vitro growth kinetics of BA.5 was comparable among the Omicron subvariants, BA.5 was much more fusogenic than BA.1 and BA.2. Airway-on-a-chip analysis showed that, among Omicron subvariants, BA.5 had enhanced ability to disrupt the respiratory epithelial and endothelial barriers. Furthermore, in our hamster model, in vivo pathogenicity of BA.5 was slightly higher than that of the other Omicron variants and less than that of ancestral B.1.1. Notably, BA.5 gains efficient virus spread compared with BA.1 and BA.2, leading to prompt immune responses. Our findings suggest that BA.5 has low pathogenicity compared with the ancestral strain but enhanced virus spread /inflammation compared with earlier Omicron subvariants.
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Contexto em Saúde: 4_TD Problema de saúde: 4_pneumonia Assunto principal: COVID-19 Tipo de estudo: Prognostic_studies Limite: Animals Idioma: En Revista: Commun Biol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Japão
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Contexto em Saúde: 4_TD Problema de saúde: 4_pneumonia Assunto principal: COVID-19 Tipo de estudo: Prognostic_studies Limite: Animals Idioma: En Revista: Commun Biol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Japão